Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

July 31, 2013

Conditions
Active Rheumatoid Arthritis
Interventions
DRUG

SBI-087

200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate

DRUG

SBI-087

200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate

DRUG

SBI-087

200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate

DRUG

SBI-087

200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate

DRUG

Placebo

Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate

Trial Locations (55)

1023

Pfizer Investigational Site, Budapest

3529

Pfizer Investigational Site, Miskolc

5000

Pfizer Investigational Site, Szolnok

5701

Pfizer Investigational Site, Gyula

11000

Pfizer Investigational Site, Belgrade

13210

Pfizer Investigational Site, Syracuse

15006

Pfizer Investigational Site, A Coruña

18205

Pfizer Investigational Site, Niška Banja

19713

Pfizer Investigational Site, Newark

21000

Pfizer Investigational Site, Novi Sad

26301

Pfizer Investigational Site, Clarksburg

27000

Pfizer Investigational Site, Coahulia

28007

Pfizer Investigational Site, Madrid

28046

Pfizer Investigational Site, Madrid

29406

Pfizer Investigational Site, Charleston

33169

Pfizer Investigational Site, Miami

34684

Pfizer Investigational Site, Palm Harbor

38305

Pfizer Investigational Site, Jackson

41009

Pfizer Investigational Site, Seville

43606

Pfizer Investigational Site, Toledo

45408

Pfizer Investigational Site, Dayton

49546

Pfizer Investigational Site, Grand Rapids

58701

Pfizer Investigational Site, Minot

62704

Pfizer Investigational Site, Springfield

74135

Pfizer Investigational Site, Tulsa

85253

Pfizer Investigational Site, Paradise Valley

87102

Pfizer Investigational Site, Albuquerque

90404

Pfizer Investigational Site, Santa Monica

91361

Pfizer Investigational Site, Westlake Village

92260

Pfizer Investigational Site, Palm Desert

99204

Pfizer Investigational Site, Spokane

7601126

Pfizer Investigational Site, Providencia

01610

Pfizer Investigational Site, Worcester

C1015ABO

Pfizer Investigational Site, Buenos Aires

C1055AAF

Pfizer Investigational Site, C.a.b.a

C1425EKG

Pfizer Investigational Site, C.a.b.a

R3A 1M3

Pfizer Investigational Site, Winnipeg

M5T 2S8

Pfizer Investigational Site, Toronto

M9L 3A2

Pfizer Investigational Site, Toronto

H9R 3J1

Pfizer Investigational Site, Pointe-Claire

Unknown

Pfizer Investigational Site, Aichi

Pfizer Investigational Site, Fukui

Pfizer Investigational Site, Fukuoka

Pfizer Investigational Site, Hokkaido

Pfizer Investigational Site, Hyōgo

Pfizer Investigational Site, Kanagawa

Pfizer Investigational Site, Miyagi

Pfizer Investigational Site, Saitama

Pfizer Investigational Site, Shizuoka

Pfizer Investigational Site, Tokyo

04-141

Pfizer Investigational Site, Warsaw

13-200

Pfizer Investigational Site, Działdowo

82-300

Pfizer Investigational Site, Elblag

81-759

Pfizer Investigational Site, Sopot

02-637

Pfizer Investigational Site, Warsaw

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Emergent Product Development Seattle LLC

INDUSTRY

lead

Pfizer

INDUSTRY

NCT01008852 - Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter